SEC Form 4 · accession 0001225208-16-042231
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A Mussallem
Officer — Chairman & CEO · Director
Period of report
Nov 22, 2016
Accepted (ET)
Nov 23, 2016 · 6:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 22, 2016 | M | 49,100 | $25.48 | A | 79,738 | D | |
| Common StockF3,F2 | Nov 22, 2016 | S | 4,700 | $86.0477 | D | 75,038 | D | |
| Common StockF4,F2 | Nov 22, 2016 | S | 18,700 | $84.18 | D | 56,338 | D | |
| Common StockF5,F2 | Nov 22, 2016 | S | 25,700 | $84.7809 | D | 30,638 | D | |
| Common StockF6 | holding | — | — | — | 123,931 | I | 401(k) | |
| Common Stock | holding | — | — | — | 676,295 | I | By Living Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Acquire)F7 | $25.48 | Nov 22, 2016 | M | 49,100 | D | Jun 13, 2010 | May 12, 2017 | Common Stock | 49,100 | 5,600 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016.
- F2This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
- F3This transaction was executed in multiple trades at prices ranging from $85.50 to $86.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $83.50 to $84.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $84.50 to $85.49. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F6Shares represented on the most recent statement of the 401(k) Plan Administrator where a unitized accounting procedure is utilized to convert the equity to share equivalents.
- F7Although the balance indicates that there are 5,600 derivative securities beneficially owned following the reported transaction, the correct number should be 294,400. This is a filing software issue which the vendor is working to correct. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.